Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

2G2F

A Src-like Inactive Conformation in the Abl Tyrosine Kinase Domain

Summary for 2G2F
Entry DOI10.2210/pdb2g2f/pdb
DescriptorAbl Kinase, ATP-Peptide Conjugate, PHOSPHOTHIOPHOSPHORIC ACID-ADENYLATE ESTER, ... (5 entities in total)
Functional Keywordsprotein kinase, transferase
Biological sourceHomo sapiens (human)
More
Cellular locationCytoplasm, cytoskeleton. Isoform IB: Nucleus membrane; Lipid-anchor: P00519
Total number of polymer chains3
Total formula weight68661.88
Authors
Levinson, N.M.,Kuchment, O. (deposition date: 2006-02-15, release date: 2006-05-23, Last modification date: 2024-11-13)
Primary citationLevinson, N.M.,Kuchment, O.,Shen, K.,Young, M.A.,Koldobskiy, M.,Karplus, M.,Cole, P.A.,Kuriyan, J.
A SRC-like inactive conformation in the abl tyrosine kinase domain.
Plos Biol., 4:753-767, 2006
Cited by
PubMed Abstract: The improper activation of the Abl tyrosine kinase results in chronic myeloid leukemia (CML). The recognition of an inactive conformation of Abl, in which a catalytically important Asp-Phe-Gly (DFG) motif is flipped by approximately 180 degrees with respect to the active conformation, underlies the specificity of the cancer drug imatinib, which is used to treat CML. The DFG motif is not flipped in crystal structures of inactive forms of the closely related Src kinases, and imatinib does not inhibit c-Src. We present a structure of the kinase domain of Abl, determined in complex with an ATP-peptide conjugate, in which the protein adopts an inactive conformation that resembles closely that of the Src kinases. An interesting aspect of the Src-like inactive structure, suggested by molecular dynamics simulations and additional crystal structures, is the presence of features that might facilitate the flip of the DFG motif by providing room for the phenylalanine to move and by coordinating the aspartate side chain as it leaves the active site. One class of mutations in BCR-Abl that confers resistance to imatinib appears more likely to destabilize the inactive Src-like conformation than the active or imatinib-bound conformations. Our results suggest that interconversion between distinctly different inactive conformations is a characteristic feature of the Abl kinase domain.
PubMed: 16640460
DOI: 10.1371/journal.pbio.0040144
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.7 Å)
Structure validation

229183

PDB entries from 2024-12-18

PDB statisticsPDBj update infoContact PDBjnumon